Company intelligence / Profile preview
Pila Pharma
Malmö, Skåne, Swedenpilapharma.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Pila Pharma develops small molecule TRPV1 antagonists as novel treatments for type 2 diabetes and other diseases with an inflammatory background. Their lead candidate, XEN-D0501, has shown promising results in preclinical models for abdominal aorta aneurysm and has orphan drug designation for erythromelalgia. The company plans further clinical studies and seeks partnerships or acquisition opportunities within the next few years[2][1].
- Therapeutic areas
- EndocrinologyCardiovascularNeurology
- Modalities
- Small molecules (TRPV1 antagonists)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Research collaboration with Uppsala University on abdominal aortic aneurysm project[1]
Beyond the preview
Go deeper on Pila Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pila Pharma.